Innate Pharma Net Interest Income Over Time
| IPHA Stock | USD 1.70 0.08 4.49% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Innate Pharma Performance and Innate Pharma Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. Market participants price Innate higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Innate Pharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.75) | Earnings Share (0.65) | Revenue Per Share | Quarterly Revenue Growth (0.61) | Return On Assets |
The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Innate Pharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Interest Income Analysis
Compare Innate Pharma and related stocks such as Cardiff Oncology, Rani Therapeutics, and Milestone Pharmaceuticals Net Interest Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRDF | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (886.1 K) | 194 K | 234.2 K | 88.3 K | 264 K | 1.6 M | 3.8 M | 3.3 M | 3.7 M | 3.9 M |
| RANI | 413 K | 413 K | 413 K | 413 K | 413 K | 413 K | 413 K | 413 K | 413 K | 413 K | (61 K) | (377 K) | 177 K | (1.1 M) | (3.3 M) | (2.9 M) | (2.8 M) |
| MIST | 186 K | 186 K | 186 K | 186 K | 186 K | 186 K | 186 K | 186 K | 711 K | 2.6 M | 726 K | 220 K | 1.3 M | 1.8 M | 583 K | 670.5 K | 1.1 M |
| CGEN | 705 K | 705 K | 705 K | 705 K | 705 K | 705 K | 705 K | 508 K | 620 K | 903 K | 1.7 M | 871 K | 1.7 M | 3.2 M | 5.2 M | 6 M | 6.3 M |
| CRBP | 477 | 477 | 477 | 477 | 477 | 477 | 477 | 183.1 K | 982.8 K | 1.2 M | (1 M) | (1.8 M) | (2.1 M) | (2.9 M) | 4.4 M | 4 M | 4.2 M |
| MOLN | 413 K | 413 K | 413 K | 413 K | 413 K | 413 K | 413 K | 413 K | 591 K | 1.5 M | 64 K | (457 K) | 523 K | 3.7 M | 3.3 M | 3.8 M | 4 M |
| NVCT | 4 K | 4 K | 4 K | 4 K | 4 K | 4 K | 4 K | 4 K | 4 K | 4 K | 4 K | 4 K | 149 K | 475 K | 847 K | 974 K | 1 M |
| APLT | 3 K | 3 K | 3 K | 3 K | 3 K | 3 K | 3 K | 3 K | (1.6 M) | 93 K | 559 K | 555 K | 685 K | 1.4 M | 3.5 M | 4.1 M | 4.3 M |
| ELTX | 81.5 K | 81.5 K | 81.5 K | 81.5 K | 81.5 K | 81.5 K | 81.5 K | 81.5 K | 81.5 K | 81.5 K | 8.9 K | (873 K) | (3.5 M) | (686 K) | (3.2 M) | (2.9 M) | (2.7 M) |
Innate Pharma and related stocks such as Cardiff Oncology, Rani Therapeutics, and Milestone Pharmaceuticals Net Interest Income description
The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.My Equities
My Current Equities and Potential Positions
| Innate Pharma | IPHA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 117, Avenue de |
| Exchange | NASDAQ Exchange |
USD 1.7
Check out Innate Pharma Performance and Innate Pharma Correlation. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Innate Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.